MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-12-2024
Agile Therapeutics DIO Ratio 2011-2026 | AGRX
Annual DIO Ratio Agile Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.7 | 61.3 | 16.4 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 82.7 | 16.4 | 53.5 |
Quarterly DIO Ratio Agile Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 291 | 176 | - | 91.1 | 93.9 | 80.7 | - | 132 | 103 | 109 | - | 116 | 201 | 66.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 291 | 66.4 | 133 |
DIO Ratio of other stocks in the Drug manufacturers industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
459 | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
133 | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
71.9 | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
48.9 | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
460 | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
100 | - | - | $ 28.9 M |  Irlanda |
 |
Canopy Growth Corporation
CGC
|
167 | $ 1.1 | 2.84 % | $ 118 M |  Canada |
 |
Evoke Pharma
EVOK
|
995 | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
58.7 | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
221 | $ 2.64 | 1.35 % | $ 1.38 B | Canada |
 |
Evolus
EOLS
|
71.3 | $ 5.68 | 37.53 % | $ 366 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
366 | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
59.7 | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
168 | $ 0.59 | 6.08 % | $ 10.3 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
239 | $ 3.81 | -16.81 % | $ 53.6 M | USA |
 |
HEXO Corp.
HEXO
|
703 | - | 2.45 % | $ 38.1 M | Canada |
 |
Harrow Health
HROW
|
65.1 | $ 40.02 | 3.65 % | $ 1.47 B | USA |
 |
Aurora Cannabis
ACB
|
1.35 K | $ 3.65 | 4.89 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
158 | - | -23.39 % | $ 1.76 M | USA |
 |
Emergent BioSolutions
EBS
|
176 | $ 8.95 | 0.39 % | $ 458 M | USA |
 |
ProPhase Labs
PRPH
|
30.1 | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
347 | $ 12.19 | 2.48 % | $ 866 M | USA |
 |
Radius Health
RDUS
|
204 | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
172 | $ 5.67 | -0.87 % | $ 2.07 B | Canada |
 |
Lannett Company
LCI
|
127 | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
149 | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
85.9 | $ 2.87 | 0.01 % | $ 378 M | USA |
 |
OrganiGram Holdings
OGI
|
2.83 K | $ 1.4 | 2.19 % | $ 402 M | Canada |
 |
Rockwell Medical
RMTI
|
28.5 | $ 0.91 | 1.03 % | $ 21.2 M | USA |
 |
Perrigo Company plc
PRGO
|
148 | $ 11.71 | 2.81 % | $ 1.62 B | USA |
 |
TherapeuticsMD
TXMD
|
1.04 K | $ 2.25 | 1.35 % | $ 23.5 M | USA |
 |
Veru
VERU
|
179 | $ 2.53 | 0.4 % | $ 341 M | USA |
 |
Viatris
VTRS
|
140 | $ 14.74 | -1.04 % | $ 17.7 B | USA |
 |
Pacira BioSciences
PCRX
|
246 | $ 22.92 | 3.69 % | $ 1.06 B | USA |
 |
PetIQ
PETQ
|
64.9 | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
370 | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
97.2 | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
49.1 | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
165 | $ 0.75 | -2.76 % | $ 3.23 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
117 | $ 2.74 | -0.36 % | $ 3.4 M | USA |
 |
Tilray
TLRY
|
170 | $ 7.33 | -0.48 % | $ 4.53 B | Canada |